MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 06:30:28 08/07/2024 pm IST | ||
| 17.94 EUR / 18.24 EUR | +0.72% |
|
| Current month | -2.29% | ||
| 1 month | +5.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/24/08 | 17.77 | -1.06% |
| 05/24/05 | 17.96 | -1.37% |
| 04/24/04 | 18.21 | -0.65% |
| 03/24/03 | 18.33 | +1.72% |
| 02/24/02 | 18.02 | -1.48% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 02:50 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB8LMF |
| ISIN | DE000JB8LMF1 |
| Date issued | 15/12/2023 |
| Strike | 667.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 23.93 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.93 € |
|---|---|
| Lowest since issue | 16.73 € |
| Spread | 0.3 € |
| Spread % | 1.65% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
